Clinical Trials
350
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (303 trials with phase data)• Click on a phase to view related trials
Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma Following Failure of First-Line Systemic Therapy
- Conditions
- HCC
- Interventions
- Drug: lparomlimab and Tuvonralimab Injection in Combination with TACE and Lenvatinib
- First Posted Date
- 2025-08-01
- Last Posted Date
- 2025-08-01
- Target Recruit Count
- 29
- Registration Number
- NCT07099274
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Induction Immunotherapy Combined With Chemotherapy Followed by Concurrent Chemoradiotherap and Immunotherapy for Cervical Cancer
- Conditions
- Cervical Cancer
- Interventions
- Radiation: Pelvic External-Beam Radiotherapy (EBRT)
- First Posted Date
- 2025-07-30
- Last Posted Date
- 2025-07-30
- Target Recruit Count
- 34
- Registration Number
- NCT07092696
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute&Hospital, Tianjin, China
The Efficacy and Safety of First-line Treatment Combined With Immunotherapy for Advanced Hepatocellular Carcinoma: a Single Center, Real-world Study
- Conditions
- Hepatocellular Carcinoma (HCC)Real World Study
- First Posted Date
- 2025-07-22
- Last Posted Date
- 2025-07-22
- Target Recruit Count
- 400
- Registration Number
- NCT07078292
Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Drug: Regorafenib and tislelizumab
- First Posted Date
- 2025-07-22
- Last Posted Date
- 2025-07-22
- Target Recruit Count
- 134
- Registration Number
- NCT07078305
Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
- Conditions
- Solid CancersRadiotherapyImmune Checkpoint InhibitorLung Cancer
- First Posted Date
- 2025-07-10
- Last Posted Date
- 2025-07-17
- Target Recruit Count
- 30
- Registration Number
- NCT07058948
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 70
- Next
News
Chinese Drug Combination Outperforms Keytruda in Advanced Lung Cancer Trial
A Chinese-developed drug combination of Benmelstobart and Anlotinib demonstrated superior efficacy over pembrolizumab (Keytruda) in treating PD-L1-positive advanced non-small cell lung cancer patients.
Phase 2 Trial Shows Promise: Camrelizumab Plus Chemotherapy Effective for Advanced Nasopharyngeal Cancer in Non-Endemic Regions
A phase 2 trial demonstrates that combining camrelizumab immunotherapy with induction chemotherapy and chemoradiotherapy achieved an 84% 3-year disease-free survival rate in advanced nasopharyngeal cancer patients.
Pyrotinib Plus Metronomic Vinorelbine Shows Efficacy in HER2+ Advanced Breast Cancer Post-Trastuzumab
A phase 2 trial in China demonstrated that pyrotinib combined with metronomic vinorelbine is effective in HER2-positive advanced breast cancer patients after trastuzumab failure.